EMPOWERING

INNOVATION

NEXT GENERATION
3D-PRINTED
AI-ENABLED
SCALEABLE BIOREACTORS

10 x CHEAPER

We’re disrupting biotech by making bioreactors 10x cheaper than anything on the market today.

100 x FASTER

We deliver 100x faster by 3D-printing bioreactors on demand, eliminating long supply chains and manufacturing bottlenecks.

1 MILLION LITRES

By 2030, we will have built 1M litres of bioreactor capacity at unprecedented speed.

Empowering innovators to solve humanity's most complex challenges.

One bioreactor at a time.

High costs and strict regulations have confined biomanufacturing to niche pharmaceutical markets.

Our affordable, efficient, user-friendly system levels the playing field.

ChainReactor combines the power of 3D printing technology and machine learning to disrupt the biotech industry. Our scaleable, cutting-edge bioreactors save time and money and increase production capacity.

Enabling research, growing your business and making breakthroughs for the planet.

SCALABLE:

from 250ml to 2kl

TECH SPECS

Desktop \\ Cloud control \\ Scriptable \\ Iterative

VESSELS

Patent Pending Polymer Vessel Sizes from 250ml to 2000 liters.

Stirred tank, Airlift and Perfusion bioreactors

Machine Vision soft sensors

CONTROL STATION

Peristaltic pumps

Cascade Control

Heating and Cooling system included

Standard sensors- PH, DO, Temperature

Agitation Control

Touchscreen Interface

MEET OUR TEAM

Nate was awarded a grant from NASA to build 3D printed surfboards from seaweed during his Imperial College PHD.  5 years later, with clients like BMW/MINI, L'Oreal and MTV, after  printing everything from motorsports parts to massive artworks, he’s focused on scaling biotech.

Nate Petre, CEO

Emma James, COO

With 10+ years in healthcare and strategy consulting, Emma has a strong mix of business and domain expertise. Her experience framing and solving complex problems for top pharma companies brings structure and focus to our disruptive team.

David Birgé-Cotte, CTO

David is a skilled hardware engineer with a focus on the biomaterial industries. With a few years of experience navigating the landscape of this dynamic sector, he understands the concerns and challenges facing the technology.